Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

NCT02271412 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder, Recurrent, Unspecified

Interventions

DRUG: LY03005
DRUG: Placebo

Sponsor

Luye Pharma Group Ltd.